로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > IGFBP-3

IGFBP-3

요약

Name:Insulin-like growth factor binding protein III
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
IG3-H52H9 Human Human IGFBP-3 Protein, His Tag
IG3-H52H9-structure
IG3-H52H9-sds

일부의 생물활성 데이터

IG3-H52H9-ELISA
 IGFBP-3 ELISA

Immobilized Biotinylated Human IGF-II, Avitag,Fc Tag (Cat. No. IG2-H82F9) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (1 μg/well) plate can bind Human IGFBP-3, His Tag (Cat. No. IG3-H52H9) with a linear range of 0.01-0.313 μg/mL (QC tested).

Synonym Name

IGFBP3,BP-53,IBP3

Background

Insulin-like growth factor-binding protein 3 is also known as IGFBP3, is a protein that, in humans, is encoded by the IGFBP3 gene. IGFBP3 forms a ternary complex of about 140 ~150 kDa with IGF1 or IGF2 and a glycoprotein insulin-like growth factor acid-labile subunit (ALS), thus alter the interaction of IGFs with their cell surface receptors. IGFBP3 exerts either proapoptotic or growth stimulatory effects depending upon the cellular context. Studies have shown that IGFBP3 can leads to the induction of apoptosis dependent or independent of the IGF-IGF receptor axis, accordingly acts as a negative regulator of tumorigenesis and progressing in certain carcinomas. The highest expression level is found in the nonparanchymal cells of the liver. Expression levels are also higher during extrauterine life and peak during puberty.

Clinical and Translational Updates

Related Molecule

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
ENT-001 Ent-001; ENT-001; Ent001 Phase 1 Clinical Ospedale San Raffaele Diabetes Mellitus, Type 1; Inflammatory Bowel Diseases Details

This web search service is supported by Google Inc.

totop